Featured Research

from universities, journals, and other organizations

Parkinson's patients' 'risky behavior' explained

Date:
June 28, 2010
Source:
University College London
Summary:
Scientists have explained Parkinson's patients' risky behavior, a rare side effect of standard treatments for the disease. The finding has implications for future medication of patients.

Scientists at UCL (University College London) have explained Parkinson's patients' risky behaviour, a rare side effect of standard treatments for the disease. The finding has implications for future medication of patients.

The standard treatments for Parkinson's disease, which work by increasing dopamine signalling in the brain, can trigger highly risky behaviours, known as 'impulsive-compulsive spectrum behaviours' (ICBs) in approximately 5-10% of patients.

New results, published June 23 in the journal Neuropsychopharmacology, uncover a possible explanation for this behaviour -- impaired self-control combined with surprisingly normal motivation. Researchers have shown that Parkinson's patients with ICBs are much more willing to take immediate but smaller benefits rather than waiting for larger ones in the future.

"Some patients end up gambling away their life savings while others run up huge credit card debts. This work sheds light on the reasons behind such behaviours, and may help to treat sufferers of Parkinson's disease in the future," said Charlotte Housden who carried out the work at UCL's Institute of Cognitive Neuroscience, and is now at the University of Cambridge.

Researchers studied a group of 36 Parkinson's disease patients, half of whom had ICBs, and compared them to a group of 20 elderly volunteers without Parkinson's disease. All the participants completed two tests: a computer game that measured motivation, on which the participants attempted to win cash by responding quickly and learning associations between pictures and money; and a questionnaire about financial decisions.

This questionnaire measured a form of impulsivity called "delay discounting," by asking whether someone would prefer receiving a smaller payment quickly, as opposed to waiting for a larger payment. For example, would you prefer to receive 50 today or 80 in a month's time?

The data revealed a clear pattern of results. Against the researchers' expectations, the Parkinson's patients who suffered from ICBs were not more motivated to win money on the computer game than the control volunteers. They were also no better at learning about which stimuli predicted money. On the other hand, they were considerably more likely to choose smaller immediate payments over larger but delayed ones on the questionnaire.

Dr Jonathan Roiser, from the UCL Institute for Cognitive Neuroscience, and supervisor of the study said: "The pattern of more impulsive choices together with intact motivation and learning suggests that ICBs may be mediated by impaired self-control, and not excessive motivation for rewards."

The researchers hope that this study might help in the identification and treatment of ICBs in the future.

Charlotte Housden explained: "Often, when neurologists identify these risky behaviours, their only option is to reduce the dose of drugs which treat the primary symptoms of Parkinson's disease, such as tremor and stiffness. However, this is far from ideal, since an inevitable consequence of this strategy is that these primary symptoms get worse. Our results suggest that treating impulsivity in Parkinson's disease patients with ICBs, for example with drugs used to treat other types of impulsive behaviours, might reduce their risky behaviours without worsening their primary symptoms."


Story Source:

The above story is based on materials provided by University College London. Note: Materials may be edited for content and length.


Journal Reference:

  1. Charlotte Housden et al. Intact Reward Learning but Elevated Delay Discounting in Parkinson's Disease Patients With Impulsive-Compulsive Spectrum Behaviors. Neuropsychopharmacology, (in press)

Cite This Page:

University College London. "Parkinson's patients' 'risky behavior' explained." ScienceDaily. ScienceDaily, 28 June 2010. <www.sciencedaily.com/releases/2010/06/100623085514.htm>.
University College London. (2010, June 28). Parkinson's patients' 'risky behavior' explained. ScienceDaily. Retrieved July 23, 2014 from www.sciencedaily.com/releases/2010/06/100623085514.htm
University College London. "Parkinson's patients' 'risky behavior' explained." ScienceDaily. www.sciencedaily.com/releases/2010/06/100623085514.htm (accessed July 23, 2014).

Share This




More Health & Medicine News

Wednesday, July 23, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Courts Conflicted Over Healthcare Law

Courts Conflicted Over Healthcare Law

AP (July 22, 2014) Two federal appeals courts issued conflicting rulings Tuesday on the legality of the federally-run healthcare exchange that operates in 36 states. (July 22) Video provided by AP
Powered by NewsLook.com
Why Do People Believe We Only Use 10 Percent Of Our Brains?

Why Do People Believe We Only Use 10 Percent Of Our Brains?

Newsy (July 22, 2014) The new sci-fi thriller "Lucy" is making people question whether we really use all our brainpower. But, as scientists have insisted for years, we do. Video provided by Newsy
Powered by NewsLook.com
Scientists Find New Way To Make Human Platelets

Scientists Find New Way To Make Human Platelets

Newsy (July 22, 2014) Boston scientists have discovered a new way to create fully functioning human platelets using a bioreactor and human stem cells. Video provided by Newsy
Powered by NewsLook.com
Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

Gilead's $1000-a-Pill Drug Could Cure Hep C in HIV-Positive People

TheStreet (July 21, 2014) New research shows Gilead Science's drug Sovaldi helps in curing hepatitis C in those who suffer from HIV. In a medical study, the combination of Gilead's Hep C drug with anti-viral drug Ribavirin cured 76% of HIV-positive patients suffering from the most common hepatitis C strain. Hepatitis C and related complications have been a top cause of death in HIV-positive patients. Typical medication used to treat the disease, including interferon proteins, tended to react badly with HIV drugs. However, Sovaldi's %1,000-a-pill price tag could limit the number of patients able to access the treatment. TheStreet's Keris Lahiff reports from New York. Video provided by TheStreet
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins